9TCC
African Horse Sickness Virus serotype 4 VP2 homotrimer
Summary for 9TCC
| Entry DOI | 10.2210/pdb9tcc/pdb |
| EMDB information | 55790 |
| Descriptor | Outer capsid protein VP2, ZINC ION (2 entities in total) |
| Functional Keywords | viral protein, serotype determinant, protective inmmunity |
| Biological source | African horse sickness virus 4 |
| Total number of polymer chains | 3 |
| Total formula weight | 377457.85 |
| Authors | Martinez-Castillo, A.,Aebischer, A.,Fu, L.,Breard, E.,Zientara, S.,Kortekaas, J.,Beer, M.,Abrescia, N.G.A. (deposition date: 2025-11-21, release date: 2026-07-22) |
| Primary citation | Martinez-Castillo, A.,Aebischer, A.,Toneatti, P.,Fu, L.,Vitour, D.,Sailleau, C.,Hoffmann, B.,Franzke, K.,Eschbaumer, M.,Weber, S.,Calvo Pinilla, E.,Ortego, J.,Gil-Carton, D.,Breard, E.,Zientara, S.,Kortekaas, J.,Beer, M.,Abrescia, N.G. Cryo-EM structure of African horse sickness virus VP2 receptor-binding protein enables nanoparticle vaccine design. Nat Commun, 2026 Cited by PubMed Abstract: African horse sickness virus (AHSV) is a lethal equine pathogen with no licensed vaccine other than vaccines containing attenuated virus, which pose safety risks. Endemic to sub-Saharan Africa, AHSV has caused epizootics in Spain and Portugal, Cyprus, Morocco, the Middle East, India and Pakistan and, most recently, Thailand. Here, we resolve the 3.11 Å cryo-EM structure of full-length VP2 from AHSV serotype 4, adopting its native triskelion architecture and shedding light on an α-helical domain anchoring the triskelion core, which is absent in other structurally characterized orbiviruses. Structure-guided mapping identified a subdomain of VP2 as a key target of neutralizing antibodies. Displayed on nanoparticles using the SpyCatcher/SpyTag technology, the domain conferred complete protection from clinical disease after viral challenge infection in mice and elicited robust and long-lasting immune responses in horses, the target species of AHSV. These findings provide a structural blueprint for the next generation of recombinant vaccines against AHSV and related orbiviruses. PubMed: 42401561DOI: 10.1038/s41467-026-75067-9 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.11 Å) |
Structure validation
Download full validation report






